SMER 28 profile

SMER 28 : A member of the class of quinazolines that is quinazoline which is substituted by a prop-2-en-1-ylnitrilo group and a bromo group at positions 4 and 6, respectively. It is a modulator of mammalian autophagy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	1560402
CHEMBL ID	494325
CHEBI ID	93943
SCHEMBL ID	13283266

Synonym
CBMICRO_021891
OPREA1_603374
EU-0073802
BIM-0021786.P001
n-allyl-6-bromoquinazolin-4-amine
BCB03_000905
PK04_181104
smr000106755
MLS000110826
CU-01000047511-3
NCGC00079175-02
BRD-K08478539-001-02-1
BRD-K08478539-001-01-3
CHEMBL494325 ,
smer28 (2)
bdbm50257750
cid_1560402
AKOS002262854
6-bromo-n-prop-2-enylquinazolin-4-amine
STK975188
6-bromo-n-(prop-2-en-1-yl)quinazolin-4-amine
HMS3263K19
28S ,
CCG-14477
HMS2384I08
307538-42-7
6-bromo-n-2-propenyl-4-quinazolinamine
smer28
LP01019
S8240
3SRB
NCGC00261704-01
tox21_501019
cambridge id 6164173
smer 28
AC-35370
SCHEMBL13283266
4-quinazolinamine, 6-bromo-n-2-propen-1-yl-
M3106
mfcd02166825
EX-A1017
DTXSID10364408
CS-5731
sr-01000453166
SR-01000453166-1
HY-100200
CHEBI:93943
smer-28
4-(allylamino)-6-bromoquinazoline
6-bromo-n-prop-2-enyl-4-quinazolinamine
n-allyl-6-bromo-4-quinazolineamine
AS-65723
smer28, >99% (hplc), solid
J-018126
BCP17486
smer-28;smer 28
Q27165697
6-bromo-n-2-propen-1-yl-4-quinazolinamine
allyl-(6-bromoquinazolin-4-yl)amine
SDCCGSBI-0021786.P002
NCGC00079175-07
A919204
BS162785

Role	Description
autophagy inducer	Any compound that induces the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
quinazolines	Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
secondary amino compound	A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
organobromine compound	A compound containing at least one carbon-bromine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	35.4813	0.1778	14.3909	39.8107	AID2147
ATAD5 protein, partial	Homo sapiens (human)	Potency	15.5720	0.0041	10.8903	31.5287	AID493106; AID493107; AID504467
TDP1 protein	Homo sapiens (human)	Potency	20.7329	0.0008	11.3822	44.6684	AID686978; AID686979
TSHR protein	Homo sapiens (human)	Potency	42.5615	0.3381	19.0466	37.9330	AID602292
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	39.8107	0.0112	12.4002	100.0000	AID1030
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	0.3548	0.2818	9.7212	35.4813	AID2326
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	9.0970	0.0015	30.6073	15,848.9004	AID1224819; AID1224820; AID1224821
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	4.7444	0.0355	20.9770	89.1251	AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	25.1189	0.0018	15.6638	39.8107	AID894
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	20.5962	0.0041	9.9848	25.9290	AID504444
huntingtin isoform 2	Homo sapiens (human)	Potency	1.1220	0.0006	18.4198	1,122.0200	AID1688
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	23.2809	0.0037	8.6189	23.2809	AID2668
geminin	Homo sapiens (human)	Potency	18.3564	0.0046	11.3741	33.4983	AID624296
lamin isoform A-delta10	Homo sapiens (human)	Potency	11.2202	0.8913	12.0676	28.1838	AID1487
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	10.0000	1.9953	25.5327	50.1187	AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Acyl-homoserine lactone acylase pvdQ	Pseudomonas aeruginosa PAO1	IC50 (µMol)	65.0000	65.0000	65.0000	65.0000	AID977608
Chain B, Acyl-homoserine lactone acylase pvdQ	Pseudomonas aeruginosa PAO1	IC50 (µMol)	65.0000	65.0000	65.0000	65.0000	AID977608
Chain A, Acyl-homoserine lactone acylase pvdQ	Pseudomonas aeruginosa PAO1	IC50 (µMol)	65.0000	65.0000	65.0000	65.0000	AID977608
Chain B, Acyl-homoserine lactone acylase pvdQ	Pseudomonas aeruginosa PAO1	IC50 (µMol)	65.0000	65.0000	65.0000	65.0000	AID977608
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]	Homo sapiens (human)	IC50 (µMol)	6.7890	1.1530	6.2803	9.9630	AID602235
transactivating tegument protein VP16 [Human herpesvirus 1]	Human alphaherpesvirus 1 (Herpes simplex virus type 1)	IC50 (µMol)	5.9580	0.9460	4.7016	9.4870	AID602236
nuclear receptor coactivator 3 isoform a	Homo sapiens (human)	IC50 (µMol)	2.2990	0.1476	4.3309	9.9200	AID602234
Huntingtin	Homo sapiens (human)	IC50 (µMol)	5.3600	0.7100	3.0350	5.3600	AID419008
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of phosphoprotein phosphatase activity	Huntingtin	Homo sapiens (human)
positive regulation of cilium assembly	Huntingtin	Homo sapiens (human)
establishment of mitotic spindle orientation	Huntingtin	Homo sapiens (human)
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	Huntingtin	Homo sapiens (human)
apoptotic process	Huntingtin	Homo sapiens (human)
Golgi organization	Huntingtin	Homo sapiens (human)
positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity	Huntingtin	Homo sapiens (human)
protein destabilization	Huntingtin	Homo sapiens (human)
vocal learning	Huntingtin	Homo sapiens (human)
positive regulation of apoptotic process	Huntingtin	Homo sapiens (human)
vesicle transport along microtubule	Huntingtin	Homo sapiens (human)
positive regulation of mitophagy	Huntingtin	Homo sapiens (human)
positive regulation of lipophagy	Huntingtin	Homo sapiens (human)
regulation of CAMKK-AMPK signaling cascade	Huntingtin	Homo sapiens (human)
positive regulation of aggrephagy	Huntingtin	Homo sapiens (human)
regulation of cAMP-dependent protein kinase activity	Huntingtin	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Huntingtin	Homo sapiens (human)
microtubule-based transport	Huntingtin	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
p53 binding	Huntingtin	Homo sapiens (human)
protein binding	Huntingtin	Homo sapiens (human)
profilin binding	Huntingtin	Homo sapiens (human)
kinase binding	Huntingtin	Homo sapiens (human)
heat shock protein binding	Huntingtin	Homo sapiens (human)
dynactin binding	Huntingtin	Homo sapiens (human)
identical protein binding	Huntingtin	Homo sapiens (human)
transmembrane transporter binding	Huntingtin	Homo sapiens (human)
dynein intermediate chain binding	Huntingtin	Homo sapiens (human)
beta-tubulin binding	Huntingtin	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
presynaptic cytosol	Huntingtin	Homo sapiens (human)
postsynaptic cytosol	Huntingtin	Homo sapiens (human)
nucleus	Huntingtin	Homo sapiens (human)
nucleoplasm	Huntingtin	Homo sapiens (human)
cytoplasm	Huntingtin	Homo sapiens (human)
early endosome	Huntingtin	Homo sapiens (human)
late endosome	Huntingtin	Homo sapiens (human)
autophagosome	Huntingtin	Homo sapiens (human)
endoplasmic reticulum	Huntingtin	Homo sapiens (human)
Golgi apparatus	Huntingtin	Homo sapiens (human)
centriole	Huntingtin	Homo sapiens (human)
cytosol	Huntingtin	Homo sapiens (human)
inclusion body	Huntingtin	Homo sapiens (human)
axon	Huntingtin	Homo sapiens (human)
dendrite	Huntingtin	Homo sapiens (human)
cytoplasmic vesicle membrane	Huntingtin	Homo sapiens (human)
perinuclear region of cytoplasm	Huntingtin	Homo sapiens (human)
protein-containing complex	Huntingtin	Homo sapiens (human)
cytoplasm	Huntingtin	Homo sapiens (human)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (63)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID506539	Effect on ATg12 level in african green monkey COS7 cells at 47 uM after 24 hrs by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506520	Inhibition of EGFP-tagged huntingtin expressed in african green monkey COS7 cells assessed as protection against protein-induced cell death at 47 uM after 48 hrs by Western blot analysis	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506534	Inhibition of mTOR phosphorylation expressed in african green monkey COS7 cells at 47 uM by Western blot analysis	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506763	Enhancement of autophagy in rat PC12 cells assessed as decrease in alpha-synuclein A53T mutant level at 5 mg/ml by densitometry	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506540	Increase in conjugated Atg12-Atg5 level in african green monkey COS7 cells at 47 uM after 24 hrs by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506550	Enhancement of rapamycin-induced clearance of alpha-synuclein A53T mutant protein in rat PC12 cells at 47 uM after 8 hrs by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506537	Effect on ATg5 level in african green monkey COS7 cells at 47 uM after 24 hrs by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506756	Enhancement of rapamycin-mediated cytostatic effect in Saccharomyces paradoxus after 48 to 96 hrs	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506546	Inhibition of proteasome activity in human HeLa cells assessed as induction of ubiquitinG76V-EGFP reporter level at 47 uM after 24 hrs by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506553	Inhibition of EGFP-tagged huntingtin aggregation expressed in african green monkey COS7 cells at 47 uM after 24 hrs by Western blot analysis in presence of 0.2 uM rapamycin	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506765	Enhancement of autophagy in rat PC12 cells assessed as decrease in alpha-synuclein A53T mutant level at 47 uM by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID419009	Inhibition of Huntingtin protein aggregation by yeast based assay	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Potent inhibitors of Huntingtin protein aggregation in a cell-based assay.
AID506515	Enhancement of autophagy in rat PC12 cells assessed as decrease in alpha-synuclein A53T mutant level at 43 uM by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506762	Enhancement of autophagy in rat PC12 cells assessed as decrease in alpha-synuclein A53T mutant level at 5 mg/ml by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506754	Enhancement of rapamycin-mediated cytostatic effect in Saccharomyces mikatae after 48 to 96 hrs	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506516	Cytotoxicity against african green monkey COS7 cells at 47 uM after 24 hrs by FACS analysis	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506526	Induction of autophagy in human HeLa cells harboring MAP1LC3 gene at 47 uM after 24 hrs by DAPI staining-based fluorescence microscopy	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506518	Inhibition of EGFP-tagged huntingtin aggregation expressed in african green monkey COS7 cells at 47 uM after 48 hrs by Western blot analysis	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506538	Effect on ATg7 level in african green monkey COS7 cells at 47 uM after 24 hrs by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506528	Increase in MAP1LC3 level in bafilomycin A1-treated human HeLa cells at 47 uM treated fro 24 hrs before bafilomycin A1 challenge by immunoblotting analysis	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506536	Effect on ATg6 level in african green monkey COS7 cells at 47 uM after 24 hrs by immunoblotting	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506522	Inhibition of EGFP-tagged huntingtin aggregation in MEF harboring Atg5 gene at 47 uM after 48 hrs by Western blot analysis	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID419008	Inhibition of Huntingtin protein aggregation by cell based assay	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Potent inhibitors of Huntingtin protein aggregation in a cell-based assay.
AID506524	Inhibition of EGFP-tagged huntingtin aggregation in Atg5-deficient MEF at 47 uM after 48 hrs by Western blot analysis	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506530	Neuroprotective activity in Drosophila melanogaster Huntington's disease model harboring huntington protein mutant assessed as protection against neurodegeneration at 100 uM	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506532	Toxicity against Drosophila melanogaster Huntington's disease model at 100 uM	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506748	Enhancement of 20 nM rapamycin-mediated cytostatic effect in yeast BY4742 after 48 to 96 hrs	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506750	Enhancement of rapamycin-mediated cytostatic effect in yeast RM11-1a after 48 to 96 hrs	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID506752	Enhancement of rapamycin-mediated cytostatic effect in Saccharomyces bayanus after 48 to 96 hrs	2007	Nature chemical biology, Jun, Volume: 3, Issue:6	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2011	ACS chemical biology, Nov-18, Volume: 6, Issue:11	Structural characterization and high-throughput screening of inhibitors of PvdQ, an NTN hydrolase involved in pyoverdine synthesis.
AID1159537	qHTS screening for TAG (triacylglycerol) accumulators in algae	2017	Plant physiology, Aug, Volume: 174, Issue:4	Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1800330	PvdQ IC50 Assay from Article 10.1021/cb5001586: \\Identification of Inhibitors of PvdQ, an Enzyme Involved in the Synthesis of the Siderophore Pyoverdine.\\	2014	ACS chemical biology, Jul-18, Volume: 9, Issue:7	Identification of inhibitors of PvdQ, an enzyme involved in the synthesis of the siderophore pyoverdine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (20.00)	29.6817
2010's	10 (50.00)	24.3611
2020's	6 (30.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
levoplast Levoplast: mixture of acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R,R))-, castor oil, celluloidin, collodion & tannins	2.15	1	C-nitro compound
hippuric acid hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl.	2.15	1	N-acylglycine	human blood serum metabolite; uremic toxin
xanthine 7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.. 9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.	2.15	1	xanthine	Saccharomyces cerevisiae metabolite
atrolactic acid atrolactic acid: see also 3-isomer; RN given refers to parent cpd without isomeric designation; structure	2.15	1	2-hydroxy monocarboxylic acid
etofylline etofylline: etophyllin appeared once in PubMed: Wien Med Wochenschr. 1986 May 15;136(9):213-8 as a combination drug with theophylline (spelt without e, theophllin)	2.15	1	oxopurine
n-acetyltryptophan N-acetyltryptophan : An N-acetylamino acid that is the N-acetyl derivative of tryptophan.	2.15	1	N-acetyl-amino acid; tryptophan derivative	metabolite
ethacridine Ethacridine: A topically applied anti-infective agent.	2.15	1	acridines
altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.	2.15	1	triamino-1,3,5-triazine
2,5-di-tert-butylhydroquinone 2,5-di-tert-butylbenzene-1,4-diol : A member of the class of hydroquinones that is benzene-1,4-diol substituted by tert-butyl groups at position 2 and 5.	2.15	1	hydroquinones
cx546 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine: structure in first source	2.15	1
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	2.15	1	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
diuron Diuron: A pre-emergent herbicide.. diuron : A member of the class of 3-(3,4-substituted-phenyl)-1,1-dimethylureas that is urea in which both of the hydrogens attached to one nitrogen are substituted by methyl groups, and one of the hydrogens attached to the other nitrogen is substituted by a 3,4-dichlorophenyl group.	2.15	1	3-(3,4-substituted-phenyl)-1,1-dimethylurea; dichlorobenzene	environmental contaminant; mitochondrial respiratory-chain inhibitor; photosystem-II inhibitor; urea herbicide; xenobiotic
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.15	1	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
ipriflavone ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.	2.15	1	aromatic ether; isoflavones	bone density conservation agent
6-anilino-5,8-quinolinedione 6-anilino-5,8-quinolinedione: structure given in first source; SRS-A & guanylate cyclase antagonist. 6-anilino-5,8-quinolinedione : A quinolone that is quinoline-5,8-dione in which the hydrogen at position 6 is replaced by an anilino group.	2.03	1	aminoquinoline; aromatic amine; p-quinones; quinolone	antineoplastic agent; EC 4.6.1.2 (guanylate cyclase) inhibitor
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.15	1	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
nocodazole [no description available]	2.15	1	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
ns 2028 NS 2028: structure in first source	2.1	1
piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.	2.15	1	N-arylpiperazine
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	2.15	1	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
prometone prometone: structure. prometon : A methoxy-1,3,5-triazine that is 6-methoxy-1,3,5-triazine-2,4-diamine in which the one of the hydrogens of each amino group is substituted by an isopropyl group.	2.15	1	diamino-1,3,5-triazine; methoxy-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
propanil Propanil: A chlorinated anilide that is used as an herbicide.. propanil : An anilide resulting from the formal condensation of the carboxy group of propanoic acid with the amino group of 3,4-dichloroaniline. It is a herbicide used for the treatment of numerous grasses and broad-leaved weeds in rice, potatoes, and wheat.	2.15	1	anilide; dichlorobenzene	herbicide
sulfadimethoxine Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.	2.15	1	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
sulfamethazine Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.	2.15	1	pyrimidines; sulfonamide antibiotic; sulfonamide	antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic
sulfathiazole Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.	2.15	1	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
testosterone [no description available]	2.15	1	3-hydroxy steroid	androgen
2-hydroxybenzylbenzimidazole 2-hydroxybenzylbenzimidazole: RN given refers to cpd without isomeric designation	2.15	1
etimizol Etimizol: A xanthine-related, putative nootropic drug.	2.15	1
nifenalol nifenalol: adrenergic beta-blocker with good antiarrhythmic properties; also tends to lower blood pressure & provide protection against angina; minor descriptor (75-86); on-line & INDEX MEDICUS search ETHANOLAMINES (75-86); RN given refers to parent cpd without isomeric designation	2.15	1	C-nitro compound
bis(4-hydroxyphenyl)sulfone bis(4-hydroxyphenyl)sulfone: structure and RN in first source. 4,4'-sulfonyldiphenol : A sulfone that is diphenyl sulfone in which both of the para hydrogens have been replaced by hydroxy groups.	2.15	1	bisphenol; sulfone	endocrine disruptor; metabolite
8-hydroxyquinoline-5-sulfonic acid 8-hydroxyquinoline-5-sulfonic acid: RN given refers to parent cpd	2.15	1
salicylanilide salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.	2.15	1	benzanilide fungicide; salicylamides; salicylanilides
2-phenylbutyric acid 2-phenylbutyric acid : A monocarboxylic acid that is butyric acid substituted by a phenyl group at position 2.	2.15	1	benzenes; monocarboxylic acid	human xenobiotic metabolite
4,4'-dimethoxybenzophenone 4,4'-dimethoxybenzophenone: structure in first source	2.15	1
6-phenyl-1,3,5-triazine-2,4-diamine 6-phenyl-1,3,5-triazine-2,4-diamine: structure in first source	2.15	1
quinaldic acid [no description available]	2.15	1	quinolinemonocarboxylic acid	human metabolite; Saccharomyces cerevisiae metabolite
N-(2-methoxyphenyl)acetamide [no description available]	2.15	1	acetamides; methoxybenzenes
fast red b Fast Red B: structure in first source. fast red B : An organosulfonate salt composed from 2-methoxy-4-nitrobenzene-1-diazonium and 5-sulfonaphthalene-1-sulfonate in a 1:1 ratio. Used for demostrating enterochromaffin in carcinoid tumours.	2.15	1
methylenebis(chloroaniline) Methylenebis(chloroaniline): Aromatic diamine used in the plastics industry as curing agent for epoxy resins and urethane rubbers. It causes bladder, liver, lung, and other neoplasms.. 4,4'-methylene-bis-(2-chloroaniline) : A chloroaniline that consists of two 2-chloroaniline units joined by a methylene bridge.	2.15	1	chloroaniline	metabolite
di-(4-aminophenyl)ether di-(4-aminophenyl)ether: structure	2.15	1	aromatic ether
diphenylguanidine diphenylguanidine: vulcanization accelerator; RN given refers to parent cpd. 1,3-diphenylguanidine : Guanidine carrying a phenyl substituent on each of the two amino groups. It is used as an accelerator in the rubber industry.	2.15	1	guanidines	allergen
4-Anilino-4-oxobutanoic acid [no description available]	2.15	1	anilide
mephobarbital Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.	2.15	1	barbiturates	anticonvulsant
etryptamine etryptamine: RN given refers to cpd without isomeric designation	2.15	1	indoles
sulfacetamide [no description available]	2.15	1
cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94	2.15	1	quinolines
2-aminobenzothiazole [no description available]	2.15	1	benzothiazoles
carzenide [no description available]	2.15	1	sulfonamide
nitrilotriacetic acid Nitrilotriacetic Acid: A derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.)	2.15	1	NTA; tricarboxylic acid	carcinogenic agent; nephrotoxic agent
n-(2-cyanoethyl)-2-phenylethylamine N-(2-cyanoethyl)-2-phenylethylamine: prodrug of 2-phenylethylamine	2.15	1
cyclooctane [no description available]	2.15	1
triphenyltetrazolium chloride 2,3,5-triphenyltetrazolium chloride : An organic chloride salt having 2,3,5-triphenyltetrazolium as the counterion.	2.15	1	organic chloride salt	dye; indicator
2,7-diacetylaminofluorene 2,7-diacetylaminofluorene: has been found to induce leukemia in animals; minor descriptor (75-84); on-line search 2-ACETYLAMINOFLUORENE/AA (75-84); Index Medicus search 2-ACETYLAMINOFLUORENE/AA (80-82), FLUORENES (75-79)	2.15	1
3,4-pyridinedicarboxylic acid 3,4-pyridinedicarboxylic acid: structure in first source	2.15	1	pyridinedicarboxylic acid
4-(benzoylamino)-2-hydroxybenzoic acid 4-(benzoylamino)-2-hydroxybenzoic acid: Bepask is calcium salt	2.15	1	benzamides
tropic acid tropic acid: acid moiety of ester alkaloids hyoscyamine & scopolamine; RN given refers to parent cpd with unspecified isomeric designation; structure. tropic acid : A 3-hydroxy monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a phenyl group, and one of the methyl hydrogens is substituted by a hydroxy group.	2.15	1	3-hydroxy monocarboxylic acid	human xenobiotic metabolite
8-hydroxy-7-iodo-5-quinolinesulfonic acid 8-hydroxy-7-iodo-5-quinolinesulfonic acid: used with iodine isotopes in radioisotope scanning; structure	2.15	1	hydroxyquinoline
1-acetylisatin 1-acetylisatin: structure in first source	2.15	1	indoledione
4-cumylphenol [no description available]	2.15	1	diarylmethane
5-methylisatin 5-methylisatin: structure in first source	2.15	1
2-hydrazinobenzothiazole [no description available]	2.15	1
1,2,3-trimethoxybenzene 1,2,3-trimethoxybenzene : A methoxybenzene that is benzene substituted by methoxy groups at positions 1, 2 and 3 respectively.	2.15	1	methoxybenzenes	plant metabolite
2-amino-5-chlorobenzophenone 2-amino-5-chlorbenzophenone: structure given in first source	2.15	1
diphenamid diphenamid: do not confuse with anti-inflammatory agent difenpiramide; structure	2.15	1	diarylmethane
4-(4-nitrobenzyl)pyridine [no description available]	2.15	1
5-methyl-3-phenylisoxazole-4-carboxylic acid 5-methyl-3-phenylisoxazole-4-carboxylic acid: has anti-tumor, antiviral, hypoglycemic, antifungal and anti-HIV activities; structure in first source	2.15	1
2-acetylbenzofuran 2-acetylbenzofuran: structure in first source	2.15	1
pyrazon pyrazon: structure; do not confuse with phenazone which is a synonym to antipyrine. chloridazon : A pyridazinone that is pyridazin-3(2H)-one substituted by an amino group at position 5, a chloro group at position 4 and a phenyl group at position 2.	2.15	1	benzenes; organochlorine compound; primary amino compound; pyridazinone	environmental contaminant; herbicide; xenobiotic
2-amino-5-nitrobenzophenone 2-amino-5-nitrobenzophenone: urinary metabolite of nitrazepam	2.15	1
(4-tert-Butyl-phenoxy)-acetic acid [no description available]	2.15	1	monocarboxylic acid
lenacil lenacil: Russian drug. herbicide : A substance used to destroy plant pests.. lenacil : A cyclopentapyrimidine that is 6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione substituted by a cyclohexyl group at position 3.	2.15	1	cyclopentapyrimidine	agrochemical; environmental contaminant; herbicide; xenobiotic
chlordesmethyldiazepam [no description available]	2.15	1	benzodiazepine
2-amino-2',5-dichlorobenzophenone 2-amino-2',5-dichlorobenzophenone: structure given in first source	2.15	1
2-(2'-hydroxyphenyl)benzimidazole 2-(2'-hydroxyphenyl)benzimidazole: structure in first source	2.15	1
4-phthalimidobutyric acid 4-phthalimidobutyric acid: teratogen; RN given refers to parent cpd	2.15	1
azabutyrone azabutyrone: Russian drug; RN given refers to parent cpd; structure	2.15	1
2-(2-hydroxyphenyl)benzothiazole 2-(1,3-benzothiazol-2-yl)phenol : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by a 2-hydroxyphenyl group at position 2.	2.15	1	benzothiazoles; phenols	geroprotector
4,5-dichlorocatechol [no description available]	2.15	1
n-butylbenzenesulfonamide N-butylbenzenesulfonamide: a neurotoxic plasticising agent. N-butylbenzenesulfonamide : A sulfonamide that is benzenesulfonamide substituted by a butyl group at the nitrogen atom. It has been isolated from the plant Prunus africana and has been shown to exhibit antiandrogenic activity.	2.15	1	sulfonamide	neurotoxin; plant metabolite
3-phenoxybenzoic acid 3-phenoxybenzoic acid: metabolite associated with exposure to pyrethroid insecticides. 3-phenoxybenzoic acid : A phenoxybenzoic acid in which the phenoxy group is meta to the carboxy group. It is a metabolite of pyrethroid insecticides.	2.15	1	phenoxybenzoic acid	human xenobiotic metabolite; marine xenobiotic metabolite
2-(2-hydroxyethylmercapto)benzothiazole 2-(2-hydroxyethylmercapto)benzothiazole: reaction product of 2-mercaptobenzothiazole, well-known rubber vulcanization accelerator; structure in first source	2.15	1
carboxin Carboxin: A systemic agricultural fungicide and seed treatment agent.. carboxin : An anilide obtained by formal condensation of the amino group of aniline with the carboxy group of 2-methyl-5,6-dihydro-1,4-oxathiine-3-carboxylic acid. A fungicide for control of bunts and smuts that is normally used as a seed treatment.	2.15	1	anilide fungicide; anilide; enamide; organosulfur heterocyclic compound; oxacycle; secondary carboxamide	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
meturin [no description available]	2.15	1
2-bromo-N-phenylbenzamide [no description available]	2.15	1	benzamides
4-chlorohippuric acid 4-chlorohippuric acid: metabolite of zomepirac; RN given refers to parent cpd	2.15	1
4-chlorophenoxyacetic acid 4-chlorophenoxyacetic acid: RN given refers to parent cpd; structure. (4-chlorophenoxy)acetic acid : A chlorophenoxyacetic acid that is phenoxyacetic acid carrying a chloro substituent at position 4.	2.15	1	chlorophenoxyacetic acid; monochlorobenzenes	phenoxy herbicide
2,5-dichloro-1,4-phenylenediamine 2,5-dichloro-1,4-phenylenediamine: structure in first source	2.15	1
metribuzin metribuzin : A member of the class of 1,2,4-triazines that is 1,2,4-triazin-5(4H)-one substituted by an amino group at position 4, tert-butyl group at position 6 and a methylsulfanyl group at position 3.	2.15	1	1,2,4-triazines; cyclic ketone; organic sulfide	agrochemical; environmental contaminant; herbicide; xenobiotic
2,5-dimethyl-3-furancarboxanilide 2,5-dimethyl-3-furancarboxanilide: structure	2.15	1
moricizine hydrochloride moricizine hydrochloride : A hydrochloride salt obtained from equimola amounts of moricizine and hydrogen chloride.	2.15	1	hydrochloride	anti-arrhythmia drug
2-benzimidazolylguanidine 2-benzimidazolylguanidine: effects chloride efflux in tissue; RN given refers to parent cpd	2.15	1	aminoimidazole
diflubenzuron Diflubenzuron: An insect growth regulator which interferes with the formation of the insect cuticle. It is effective in the control of mosquitoes and flies.. diflubenzuron : A benzoylurea insecticide that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 4-chlorophenyl group, and a hydrogen attached to the other nitrogen is replaced bgy a 2,6-difluorobenzoyl group.	2.15	1	benzoylurea insecticide; monochlorobenzenes	insect sterilant
pentafluorobenzoyl-n-phenylethylamine [no description available]	2.15	1
thidiazuron [no description available]	2.15	1	ureas
phenthiazamine phenthiazamine: RN given refers to parent cpd	2.15	1
5,5-diphenylbarbituric acid 5,5-diphenylbarbituric acid: RN given refers to parent cpd	2.15	1
3-acetamidobenzoic acid N-acetyl-m-aminobenzoic acid: from Solanum laciniatum; structure in first source	2.15	1
dazoxiben hydrochloride [no description available]	2.15	1
succinylsulfanilamide [no description available]	2.15	1
benzylaminopurine benzylaminopurine: a plant growth regulator. N-benzyladenine : A member of the class of 6-aminopurines that is adenine in which one of the hydrogens of the amino group is replaced by a benzyl group.	2.15	1	6-aminopurines	cytokinin; plant metabolite
ciprofloxacin hydrochloride anhydrous [no description available]	2.15	1	hydrochloride	antibacterial drug; antiinfective agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
src-820 r [no description available]	2.15	1
n(4)-acetylsulfadiazine N(4)-acetylsulfadiazine: main metabolite of sulfadiazine. N(4)-acetylsulfadiazine : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a pyrimidin-2-yl group at the nitrogen atom. It is a metabolite of the drug sulfadiazine.	2.15	1	acetamides; pyrimidines; sulfonamide	marine xenobiotic metabolite
4-nitro-alpha-acetylamino-beta-hydroxypropiophenone 4-nitro-alpha-acetylamino-beta-hydroxypropiophenone: inhibitory agent for the differentiation of mammalian tuberculosis strains from other Mycobacteria	2.15	1
formetamide formetamide: RN given refers to cpd with unspecified isomeric designation	2.15	1
isbufylline isbufylline: RN from Toxlit	2.15	1
phenylacetylglycine phenylacetylglycine : A N-acylglycine that is glycine substituted on nitrogen with a phenylacetyl group.	2.15	1	monocarboxylic acid amide; monocarboxylic acid; N-acylglycine	human metabolite; mouse metabolite
N-benzoylanthranilic acid N-benzoylanthranilic acid : An amidobenzoic acid comprising benzoic acid having a benzamido group at the 2-position.	2.15	1	amidobenzoic acid
butinoline [no description available]	2.15	1	diarylmethane
n-(2-carboxyphenyl)glycine [no description available]	2.15	1
n,n-dimethyl-4-anisidine [no description available]	2.15	1
n-benzoylpiperidine [no description available]	2.15	1	benzamides; N-acylpiperidine
2-phenylcyclopropanecarboxylic acid 2-phenylcyclopropanecarboxylic acid: RN given for (trans)-isomer; structure in first source	2.15	1
n-demethylantipyrine [no description available]	2.15	1	pyrazoles; ring assembly
3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine [no description available]	2.15	1	1,2,4-triazines
2-amino-5-bromopyridine [no description available]	2.15	1
n-benzoylalanine, (dl-ala)-isomer [no description available]	2.15	1	alanine derivative; N-acyl-amino acid	metabolite
bicinchoninic acid [no description available]	2.15	1
betamipron [no description available]	2.15	1	organonitrogen compound; organooxygen compound
benzoylpropionic acid benzoylpropionic acid: structure in first source. 4-oxo-4-phenylbutyric acid : A 4-oxo monocarboxylic acid that is butyric acid bearing oxo and phenyl substituents at position 4.	2.15	1	4-oxo monocarboxylic acid	hapten
Evoxine [no description available]	2.15	1	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid: precursor of mutagenic nitroso cpd in soy sauce; structure given in first source	2.15	1	harmala alkaloid
N-Benzylphthalimide [no description available]	2.15	1	isoindoles
pyromellitic diimide pyromellitic diimide: RN given refers to parent cpd	2.15	1
4'-bromosalicylanilide 4'-bromosalicylanilide: photoproduct from UV-irradiation of tribromsalan; structure	2.15	1
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane: methoxychlor metabolite	2.15	1	bisphenol
terephthalamide [no description available]	2.15	1	benzenedicarboxamide
3(2h)-pyridazinone, 4-chloro-5-(dimethylamino)-2-phenyl- [no description available]	2.15	1
2-nitrophenylacetic acid (2-nitrophenyl)acetic acid : A member of the class of phenylacetic acids that is phenylacetic acid in which the phenyl grup is substituted at the ortho- position by a nitro group.	2.15	1	C-nitro compound; phenylacetic acids
onychine [no description available]	2.15	1
4'-methoxyflavone 4'-methoxyflavone: from seeds of Psoralea corylifolia (Fabaceae); structure in first source	2.15	1	ether; flavonoids
1,3-diphenyl-2-aminopropane 1,3-diphenyl-2-aminopropane: structure given in the first source	2.15	1
2,2-diphenylpropionic acid 2,2-diphenylpropionic acid: RN given refers to parent cpd	2.15	1
3,4-dimethoxyphenylacetamide 3,4-dimethoxyphenylacetamide: structure	2.15	1
2-amino-5-bromobenzoic acid 2-amino-5-bromobenzoic acid: structure in first source	2.15	1
2-(1H-benzimidazol-2-yl)aniline 2-(1H-benzimidazol-2-yl)aniline : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a 2-aminophenyl group at position 2.	2.15	1	benzimidazoles; primary arylamine; substituted aniline	geroprotector
N-Acetylhomoveratrylamine [no description available]	2.15	1	acetamides
2-chlorobenzenesulfonamide [no description available]	2.15	1
4-nitrophenyl dimethylcarbamate [no description available]	2.15	1
8-(4-tolylsulfonylamino)quinoline 8-(4-tolylsulfonylamino)quinoline: has diabetogenic properties; can be used for fluorometric determination of zinc; structure given in first source	2.15	1	sulfonamide
5-methoxyindole-3-carbaldehyde [no description available]	2.15	1	indoles
2-oxo-1,2-dihydroquinoline-4-carboxylic acid [no description available]	2.15	1	quinolinemonocarboxylic acid
6-methoxy-2,3,4,9-tetrahydropyrido[3,4-b]indol-1-one [no description available]	2.15	1	beta-carbolines
pd 147953 [no description available]	2.15	1
fenozan fenozan: do not confuse with the phenothiazine phenosan	2.15	1
5-phenylbarbituric acid 5-phenylbarbituric acid: RN given refers to parent cpd	2.15	1
diethylpropion hydrochloride diethylpropion hydrochloride : The hydrochloride salt of diethylpropion. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as an anoretic in the short term management of obesity.	2.15	1	hydrochloride	appetite depressant
1-(4'-nitrophenyl)-2-aminopropane-1,3-diol 1-(4'-nitrophenyl)-2-aminopropane-1,3-diol: chloramphenicol minus dichloroacetamide side chain; RN given refers to cpd without isomeric designation	2.15	1
beta-hydroxyphenylalanine beta-hydroxyphenylalanine: RN given refers to beta cpd	2.15	1
3-(n-salicyloyl)amino-1,2,4-triazole 3-(N-salicyloyl)amino-1,2,4-triazole: synthetic chelating agent used chiefly to inhibit corrosion of copper	2.15	1
7-chloro-4-aminoquinoline 7-chloro-4-aminoquinoline: structure given in first source	2.15	1	aminoquinoline
acridine-9-carboxylic acid [no description available]	2.15	1
1-phenazinecarboxylic acid 1-phenazinecarboxylic acid: from Streptomyces cinnamonensis; RN given refers to parent cpd; structure given in first source. phenazine-1-carboxylic acid : An aromatic carboxylic acid that is phenazine substituted at C-1 with a carboxy group.	2.15	1	aromatic carboxylic acid; monocarboxylic acid; phenazines	antifungal agent; antimicrobial agent; bacterial metabolite
4,5-diphenyl-1,5-dihydroimidazol-2-one [no description available]	2.15	1	stilbenoid
2-hydroxy-1,2-bis(methoxyphenyl)ethanone 2-hydroxy-1,2-bis(methoxyphenyl)ethanone: structure given in first source	2.15	1
4-methyl-N-(phenylmethyl)benzenesulfonamide [no description available]	2.15	1	sulfonamide
4-n-butylaminobenzoic acid 4-n-butylaminobenzoic acid: degradation product of tetracaine. 4-(butylamino)benzoic acid : 4-Aminobenzoic acid in which one of the hydrogens attached to the nitrogen is substituted by a butyl group.	2.15	1	aromatic amino acid
fluoren-9-ol [no description available]	2.15	1
1-(2-carboxyethyl)uracil [no description available]	2.15	1
1-benzylindole 1-benzylindole: structure	2.15	1
2,3-bis(2-pyridinyl)quinoxaline [no description available]	2.15	1	quinoxaline derivative
3,3',5,5'-tetrachlorobiphenyl-4,4'-diol 3,3',5,5'-tetrachlorobiphenyl-4,4'-diol : A member of the class of hydroxybiphenyls formed formally by chlorination of biphenyl-4,4'-diol at C-3, -3', -5 and -5'.	2.15	1	dichlorobenzene; hydroxybiphenyls
5-nitro-2-(1-piperidinyl)pyridine [no description available]	2.15	1	C-nitro compound
2-amino-5,7-dimethyl-1,8-naphthyridine 2-amino-5,7-dimethyl-1,8-naphthyridine: structure in first source	2.15	1
5-benzyloxytryptophan [no description available]	2.15	1
2,5-diethoxy-4-morpholinoaniline 2,5-diethoxy-4-morpholinoaniline: structure in first source	2.15	1
3-hydroxy-3-phenacyloxindole [no description available]	2.15	1
carbobenzoxyphenylalanine, (dl-phe)-isomer [no description available]	2.15	1
gamma-fagarine gamma-fagarine: active alkaloid of Chinese medicines from Dictamni radicis cortex (Rutaceae); structure given in first source	2.15	1	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
3-carboxymethyl-6-benzyl-2,5-diketopiperazine 3-carboxymethyl-6-benzyl-2,5-diketopiperazine: formed in aqueous solution by aspartame; structure given in first source	2.15	1	organonitrogen compound; organooxygen compound
4-fluorobenzenesulfonamide 4-fluorobenzenesulfonamide: structure given in first source	2.15	1
emoxypine succinate emoxypine succinate: has antihypoxic effects	2.15	1
n-carbamyltryptophan N-carbamyltryptophan: RN given refers to (D)-isomer	2.15	1
2,4,6-trimethoxyacetophenone 2,4,6-trimethoxyacetophenone: structure in first source	2.15	1
1-(2-hydroxyethyl)-3,5-diphenyl-1h-pyrazole 1-(2-hydroxyethyl)-3,5-diphenyl-1H-pyrazole: structure given in first source	2.15	1
4-methyoxybenzoyl-n-glycine [no description available]	2.15	1	N-acylglycine
5-ethoxy-2-ethylmercaptobenzimidazole 5-ethoxy-2-ethylmercaptobenzimidazole: has activating effect on peritoneal macrophages; RN given does not give position for ethoxy group	2.15	1
5(6)-1(2h)-phthalazinonyl-4(1h)-benzimidazole-2-carbamate methyl ester [no description available]	2.15	1
n-phenyliminodiacetic acid [no description available]	2.15	1
teomorfolin teomorfolin: structure given in first source	2.15	1
1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone [no description available]	2.15	1	benzodioxoles
n-(aminocarbonyl)-2-chlorobenzenesulfonamide [no description available]	2.15	1
3-hydroxy-2-quinoxalinepropionic acid [no description available]	2.15	1
8-(methylsulfonylamino)quinoline 8-(methylsulfonylamino)quinoline: has diabetogenic properties; structure given in first source	2.15	1
n(4)-acetylsulfamonomethoxine N(4)-acetylsulfamonomethoxine: main urinary metabolite of sulfamonomethoxine in pigs	2.15	1
8-(4-benzenesulfonylamino)quinoline 8-(4-benzenesulfonylamino)quinoline: has diabetogenic properties; structure given in first source	2.15	1
methindione methindione: used in treatment of epilepsy; RN given refers to parent cpd; structure	2.15	1
3,4-dihydroxybenzophenone 3,4-dihydroxybenzophenone: structure in first source	2.15	1
gamma-propanol [no description available]	2.15	1
2-[(3-oxo-1-cyclohexenyl)amino]benzonitrile [no description available]	2.15	1	benzenes; nitrile
isonicotinylamide gaba [no description available]	2.15	1
5-fluorotryptamine monohydrochloride [no description available]	2.15	1
4-iodo-n-(2-(4-morpholinyl)ethyl)benzamide 4-iodo-N-(2-(4-morpholinyl)ethyl)benzamide: the iodinated analog of moclobemide; structure given in first source	2.15	1
3-(hydroxyacetyl)indole 3-(hydroxyacetyl)indole: structure in first source	2.15	1	indoles
n-(4-aminophenylsulfonyl)morpholine compound 82 208: structure given in first source	2.15	1
1H-indol-3-yl-(4-methoxyphenyl)methanone [no description available]	2.15	1	N-acylindole
2-amino-5-phenyl-1,3,4-thiadiazole 2-amino-5-phenyl-1,3,4-thiadiazole: structure in first source	2.15	1
N-(1-phenylethyl)acetamide N-(1-phenylethyl)acetamide : A member of the class of acetamides resulting from the formal condensation of the amino group of 1-phenylethylamine with 1 mol eq. of acetic acid.	2.15	1	acetamides; secondary carboxamide
alpha-(trichloromethyl)-4-pyridineethanol alpha-(trichloromethyl)-4-pyridineethanol: activates caspase-3	2.15	1	pyridines
ml 204 ML 204: modulates both TRPC4 and TRPC5 channels; structure in first source	2.15	1
eudesmin eudesmin: RN refers to (1R-(1alpha,3aalpha,4alpha,6aalpha))-isomer; structure given in first source; very similar to pinoresinol	2.15	1
2-amino-4-methyl-3-nitropyridine [no description available]	2.15	1
anisomycin Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.	2.03	1	monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic	anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor
4,4-bis(hydroxymethyl)-2-phenyl-2-oxazoline 4,4-bis(hydroxymethyl)-2-phenyl-2-oxazoline: Anticonvulsant	2.15	1
n-acetylhistidine [no description available]	2.15	1	histidine derivative; N-acetyl-amino acid
1-(1-oxo-2-phenylethyl)-4-piperidinecarboxylic acid [no description available]	2.15	1	acetamides
1-(4-chlorophenyl)-3-(2-ethoxyphenyl)urea [no description available]	2.15	1	ureas
4-methoxyxanthone 4-methoxyxanthone: a vasodilator; structure in first source	2.15	1
N-(4-nitrophenyl)-2-phenoxyacetamide [no description available]	2.15	1	C-nitro compound
1-phenylindolin-2-one 1-phenylindolin-2-one: structure in first source	2.15	1
1-(benzenesulfonyl)indole [no description available]	2.15	1	sulfonamide
2,4,4,6-Tetramethyl-1,4-dihydro-3,5-pyridinedicarbonitrile [no description available]	2.15	1	dihydropyridine
pifithrin mu 2-phenylacetylenesulfonamide: induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia cells; also inhibits Hsp70 and autophagy	2.15	1	benzenes
2-benzyloxybenzaldehyde [no description available]	2.15	1
2-guanidine-4-methylquinazoline 2-guanidine-4-methylquinazoline: structure given in first source	2.15	1
N-phenylcarbamic acid 2-phenoxyethyl ester [no description available]	2.15	1	carbamate ester
3,4-dihydro-2H-benzo[4,5]imidazo[2,1-b][1,3]thiazin-3-ol [no description available]	2.15	1	benzimidazoles
mequindox Mequindox: a synthetic quinoxaline 1,4-dioxide derivative which can effectively improve growth and feed efficiency in animals; structure in first source	2.15	1
N-[2-(dimethylamino)ethyl]-2,2-diphenylacetamide [no description available]	2.15	1	diarylmethane
Girgensonine [no description available]	2.15	1	nitrile
Dubinidine [no description available]	2.15	1	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
N-[4-(methanesulfonamido)phenyl]acetamide [no description available]	2.15	1	sulfonamide
4-(2-oxazolo[4,5-b]pyridinyl)aniline [no description available]	2.15	1	1,3-oxazoles
2-[(4-nitrophenyl)methylthio]-1,3-benzoxazole [no description available]	2.15	1	benzoxazole
evp 4593 EVP 4593: an NF-kappaB pathway inhibitor; structure in first source	2.05	1
3-oxido-4,5-dihydro-[1,2,5]oxadiazolo[3,4-f]cinnolin-3-ium [no description available]	2.15	1	pyridazines
3-(2,4-difluoroanilino)-5,5-dimethyl-1-cyclohex-2-enone [no description available]	2.15	1	substituted aniline
1-phenyl-4-pyrazolol [no description available]	2.15	1	pyrazoles; ring assembly
3-(3,5-dimethyl-1-pyrazolyl)-1,2-benzothiazole 1,1-dioxide [no description available]	2.15	1	benzothiazoles
3-benzamido-2-benzofurancarboxamide [no description available]	2.15	1	benzofurans
N-[2-(4-methoxyphenyl)ethyl]acetamide [no description available]	2.15	1	acetamides
N-[2-(3-methylphenoxy)ethyl]-1H-1,2,4-triazole-5-carboxamide [no description available]	2.15	1	aromatic ether
2-(1H-indol-3-ylthio)acetic acid [no description available]	2.15	1	indoles
3-bromo-N-[2-(4-nitroanilino)ethyl]benzamide [no description available]	2.15	1	carbonyl compound; organohalogen compound
3-Methylbenzofuran-2-carboxylic acid [no description available]	2.15	1	benzofurans
5-(3,4-dimethoxyphenyl)-2H-tetrazole [no description available]	2.15	1	tetrazoles
1-(4-fluorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine [no description available]	2.15	1	piperazines
4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol [no description available]	2.15	1	alkylbenzene
2-phenylindole-3-carbaldehyde 2-phenylindole-3-carbaldehyde: structure in first source	2.15	1
4-(2-pyridinylthio)benzofuro[3,2-d]pyrimidine [no description available]	2.15	1	aryl sulfide
5-(4-nitrophenyl)-4-phenyl-2-thiazolamine [no description available]	2.15	1	C-nitro compound
3-[6-(4-aminophenyl)-2-phenyl-4-pyrimidinyl]aniline [no description available]	2.15	1	pyrimidines
7-methoxyisoflavone 7-methoxyisoflavone : A methoxyisoflavone that is isoflavone substituted by a methoxy group at position 7.	2.15	1	7-methoxyisoflavones
LSM-32392 [no description available]	2.15	1	monoterpenoid
N-[2-(1-cyclohexenyl)ethyl]-4-(4-morpholinylmethyl)benzamide [no description available]	2.15	1	benzamides
1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanol [no description available]	2.15	1	benzimidazoles
N-[2-(2-furanylmethylthio)ethyl]-4-methoxybenzenesulfonamide [no description available]	2.15	1	sulfonamide
3-acetamido-5-chloro-2-benzofurancarboxylic acid [no description available]	2.15	1	benzofurans
[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-(2,6-dimethoxyphenyl)methanone [no description available]	2.15	1	dimethoxybenzene
4-[4-methyl-6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]morpholine [no description available]	2.15	1	N-arylpiperazine
haplamine haplamine: isolated from Haplophyllum acutifolium; structure in first source	2.15	1	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
5-(3,4-dimethoxyphenyl)-1H-1,2,4-triazol-3-amine [no description available]	2.15	1	triazoles
2-ethoxy-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide [no description available]	2.15	1	benzamides
2-[(5-methyl-1H-1,2,4-triazol-3-yl)thio]-1-phenylethanone [no description available]	2.15	1	aromatic ketone
1-ethyl-6-methoxy-4-oxo-3-quinolinecarboxylic acid [no description available]	2.15	1	quinolines
2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline 2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline : A member of the class of quinazolines that is quinazoline which is substituted at positions 2 and 4 by pyridin-4-yl and pyrrolidin-1-yl groups, respectively.	2.15	1	pyridines; pyrrolidines; quinazolines
scp 1 [no description available]	2.15	1
N-(3-acetamidophenyl)-4-methoxybenzamide [no description available]	2.15	1	benzamides
N-(3-acetamidophenyl)-3-chlorobenzamide [no description available]	2.15	1	benzamides
4-methoxy-N-(5-methyl-3-isoxazolyl)benzamide [no description available]	2.15	1	benzamides
N-(2-fluorophenyl)-4-phenylmethoxybenzamide [no description available]	2.15	1	benzamides
N-[4-(diethylamino)phenyl]-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
N-(2-furanylmethyl)-2-benzofurancarboxamide [no description available]	2.15	1	benzofurans
5-(2-phenylethyl)-1,3,4-thiadiazol-2-amine [no description available]	2.15	1	aromatic amine; thiadiazoles
te 5 [no description available]	2.15	1
2-[[anilino(oxo)methyl]amino]-4,5-dimethyl-3-thiophenecarboxamide [no description available]	2.15	1	ureas
N-(4,6-dimethyl-2-pyrimidinyl)-1,3-benzothiazol-2-amine [no description available]	2.15	1	benzothiazoles
6-methylflavone 6-methylflavone: structure in first source	2.15	1
2-methoxy-N-(2-pyridinyl)benzamide [no description available]	2.15	1	benzamides
2-chloro-N-(2-phenylethyl)benzamide [no description available]	2.15	1	carbonyl compound; organohalogen compound
N1-(4H-1,2,4-triazol-4-yl)-4-nitrobenzamide [no description available]	2.15	1	C-nitro compound
N-[2-(1-cyclohexenyl)ethyl]-4-fluorobenzamide [no description available]	2.15	1	carbonyl compound; organohalogen compound
tioxazafen tioxazafen : A 1,2,4-oxadizole in which the hydrogens at positions 3 and 5 have been replaced by phenyl and thiophen-2-yl groups, respectively. It is used as a broad spectrum nematicidal seed treatment.	2.15	1	1,2,4-oxadiazole; thiophenes	agrochemical; nematicide
N-[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]-2-thiophen-2-ylacetamide [no description available]	2.15	1	aromatic amide
1-(4-Methoxyphenyl)-2-nitroethylene 4-methoxy-beta-nitrostyrene: has vasodilator activity; structure in first source	2.15	1	methoxybenzenes
brd32048 BRD32048: inhibits ETV1 oncoprotein; structure in first source	2.15	1	methoxybenzenes; substituted aniline
2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide [no description available]	2.15	1	aromatic ether
2-(3,4-dichlorophenyl)imidazo[1,2-a]pyrimidine [no description available]	2.15	1	imidazoles
5-(2-phenyl-4-triazolyl)-2H-tetrazole [no description available]	2.15	1	triazoles
N-cyclohexyl-2,3-dihydroindole-1-carboxamide [no description available]	2.15	1	indolyl carboxylic acid
4-(benzylsulfanyl)thieno[2,3-d]pyrimidine 4-(benzylsulfanyl)thieno[2,3-d]pyrimidine : A thienopyrimidine that is thieno[2,3-d]pyrimidine which is substituted at position 4 by a benzylsulfanediyl group.	2.15	1	aryl sulfide; benzenes; thienopyrimidine
2-methyl-5-(5-methyl-2-furanyl)-3-(1-pyrrolyl)-4-thieno[2,3-d]pyrimidinone [no description available]	2.15	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
1-[2-(dimethylamino)ethyl]-5-methoxy-N-methyl-2-indolecarboxamide [no description available]	2.15	1	indolecarboxamide
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-methoxybenzamide [no description available]	2.15	1	benzamides
4-(1H-benzimidazol-2-yl)quinoline [no description available]	2.15	1	quinolines
1-(4-Chlorophenyl)-2-[(1-methyl-1H-imidazol-2-yl)thio]ethan-1-one [no description available]	2.15	1	aromatic ketone
N-(2,5-dimethylphenyl)-2-benzofurancarboxamide [no description available]	2.15	1	aromatic amide; furans
N-(4-methoxyphenyl)-2-benzofurancarboxamide [no description available]	2.15	1	aromatic amide; furans
2-(9h-xanthen-9-yl)-malonic acid [no description available]	2.15	1	xanthenes
1-(1,3-benzothiazol-2-yl)-3-phenylurea [no description available]	2.15	1	ureas
1-hydroxy-2-phenyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one [no description available]	2.15	1	imidazoles
N-(4-acetamidophenyl)-2-bromobenzamide [no description available]	2.15	1	benzamides
4-bromo-N-phenacylbenzamide [no description available]	2.15	1	aromatic ketone
1-(2,3-dihydroindol-1-yl)-2-(phenylthio)ethanone [no description available]	2.15	1	indoles
N-[6-methyl-2-(4-methylphenyl)-5-benzotriazolyl]-3-pyridinecarboxamide [no description available]	2.15	1	triazoles
N,N-dimethyl-N'-p-tolylsulfamide N,N-dimethyl-N'-p-tolylsulfamide : A member of the class of sulfamides that is N,N-dimethylsulfuric diamide substituted by a 4-methylphenyl group at the amino nitrogen atom. It is a metabolite of the agrochemical tolylfluanid.	2.15	1	sulfamides	marine xenobiotic metabolite
2-(1-piperidinylmethyl)phenol 2-(1-piperidinylmethyl)phenol: structure in first source	2.15	1
2,6-bis(benzimidazol-2-yl)pyridine 2,6-bis(benzimidazol-2-yl)pyridine: structure in first source	2.15	1	benzimidazoles
1-cyclohexyl-3-(2-phenylethyl)urea [no description available]	2.15	1	benzenes
1-(3,5-dichlorophenyl)-3-phenylurea [no description available]	2.15	1	ureas
1-(cyclohexylmethyl)-4-phenylpiperazine [no description available]	2.15	1	piperazines
N-phenethyl-2-furamide [no description available]	2.15	1	aromatic amide; heteroarene
paromomycin sulfate [no description available]	2.15	1
N,N,2-trimethyl-1-phenyl-5-benzimidazolesulfonamide [no description available]	2.15	1	benzimidazoles
N-(phenylmethyl)-4-(3-pyridinyl)-2-thiazolamine [no description available]	2.15	1	aralkylamine
N-(4-hydroxy-2-methyl-5-propan-2-ylphenyl)benzenesulfonamide [no description available]	2.15	1	monoterpenoid
2-amino-5-ethyl-4-(2-furanyl)-6-propyl-3-pyridinecarbonitrile [no description available]	2.15	1	nitrile; pyridines
2-ethoxy-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]benzamide [no description available]	2.15	1	benzamides
vu0099704 VU0099704: an antagonist of protease activated receptor 4 (PAR-4); structure in first source	2.15	1
3-(4-chlorophenyl)-2,5-dimethyl-1H-pyrazolo[1,5-a]pyrimidin-7-one [no description available]	2.15	1	pyrazoles; ring assembly
1-(2-chloro-6-fluorophenyl)-[1,2,4]triazolo[4,3-a]quinoline [no description available]	2.15	1	triazoles
2-methyl-N-(1-methyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)propanamide [no description available]	2.15	1	pyrroloquinoline
2-methyl-5-[(2-methyl-4-quinolinyl)thio]-1,3,4-thiadiazole [no description available]	2.15	1	aryl sulfide
5-methyl-1-(4-nitrophenyl)-2-oxo-2,5-dihydro-1h-pyrido(3,2-b)indole-3-carbonitrile VRX-413638: structure in first source	2.15	1
(3-hydroxy-5,6,7,8-tetrahydro-4H-cyclohepta[d]imidazol-2-yl)-phenylmethanone [no description available]	2.15	1	aromatic ketone
2-fluoro-N-phenacylbenzamide [no description available]	2.15	1	aromatic ketone
4-(methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrile [no description available]	2.15	1	nitrile; pyridines
1-azepanyl-[2-methoxy-4-(methylthio)phenyl]methanone [no description available]	2.15	1	carbonyl compound; thiol
GS4012 free base GS4012 free base : A member of the class of pyridines that is 2-(pyridin-4-yl)ethane-1-thiol in which the thiol hydrogen is replaced by a 4-methoxyphenyl group.	2.15	1	aryl sulfide; monomethoxybenzene; pyridines	VEGF activator
N-[1-(4-methylphenyl)-5-benzimidazolyl]acetamide [no description available]	2.15	1	benzimidazoles
2-(4-methylanilino)-1-(4-nitrophenyl)ethanone [no description available]	2.15	1	aromatic ketone
N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide : An amino acid amide obtained by the formal condensation of 2,6-dimethylaniline with N-(3,5-dimethylphenyl)glycine.	2.15	1	amino acid amide; glycine derivative
2-[4-[(3-fluorophenyl)methyl]-1-piperazinyl]pyrimidine [no description available]	2.15	1	N-arylpiperazine
1-[(3,4-dimethoxyphenyl)methyl]-4-(2,3-dimethylphenyl)piperazine [no description available]	2.15	1	piperazines
4-Piperidinobenzoic acid [no description available]	2.15	1	piperidines
1-(2-methoxyphenyl)-4-(3-thiophenylmethyl)piperazine [no description available]	2.15	1	piperazines
N-(1-methyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)-2-(1-pyrrolidinyl)acetamide [no description available]	2.15	1	pyrroloquinoline
4-[(1H-benzimidazol-2-ylthio)methyl]-2-thiazolamine [no description available]	2.15	1	benzimidazoles
4-[(4-phenyl-2-thiazolyl)amino]benzenesulfonamide [no description available]	2.15	1	sulfonamide
N-[7-(1-oxopropyl)-2,3-dihydro-1,4-benzodioxin-6-yl]benzamide [no description available]	2.15	1	benzodioxine
N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: an SK channel inhibitor	2.15	1
8-(3,5-dimethyl-1-pyrazolyl)quinoline [no description available]	2.15	1	quinolines
2'-nitroflavone 2'-nitroflavone: has antineoplastic activity	2.15	1
N-(4-methoxyphenyl)-3,4-dihydroquinolin-2-amine [no description available]	2.15	1	aminoquinoline
1-(3-nitrophenyl)-3-phenyl-2-propyn-1-one [no description available]	2.15	1	aromatic compound
vrt 532 VRT 532: a CFTR potentiator; structure in first source	2.15	1
4-[[4-(2,5-dimethylphenyl)-1-piperazinyl]methyl]-2-methoxyphenol [no description available]	2.15	1	piperazines
1-piperonylpiperidine 1-piperonylpiperidine: an AMPA receptor modulator; structure in first source	2.15	1
2-[(3-fluorophenyl)methyl-(phenylmethyl)amino]ethanol [no description available]	2.15	1	aromatic amine
2-methoxy-4-[[2-(methylthio)anilino]methyl]phenol [no description available]	2.15	1	aromatic amine
6-ethyl-5-methyl-2-thiophen-2-yl-1H-pyrazolo[1,5-a]pyrimidin-7-one [no description available]	2.15	1	pyrazolopyrimidine
N-[4-(2-methyl-4-thiazolyl)phenyl]benzamide [no description available]	2.15	1	benzamides
N-(6-phenyl-5-imidazo[2,1-b]thiazolyl)benzamide [no description available]	2.15	1	imidazoles
2-(phenylmethylthio)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole [no description available]	2.15	1	aryl sulfide
5-methyl-N-(4,5,6-trimethyl-2-pyrimidinyl)-1,3-benzoxazol-2-amine [no description available]	2.15	1	benzoxazole
1-(4-methoxyphenyl)-3-(6-methyl-2-pyridinyl)urea [no description available]	2.15	1	ureas
2-{[hydroxy(2-methoxyphenyl)methylidene]amino}acetic acid [no description available]	2.15	1	N-acylglycine
(4-methoxyphenyl)-(3-methyl-2-propyl-4-imidazolyl)methanone [no description available]	2.15	1	aromatic ketone
N-(3-acetamidophenyl)-2-chlorobenzamide [no description available]	2.15	1	benzamides
N4,N4-dimethyl-N1-(4-nitro-1,1-dioxo-2,5-dihydrothiophen-3-yl)benzene-1,4-diamine [no description available]	2.15	1	dialkylarylamine; tertiary amino compound
2-bromo-N-(3-methoxyphenyl)benzamide [no description available]	2.15	1	benzamides
2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)methyl]-6-nitrophenol [no description available]	2.15	1	aromatic ether; C-nitro compound
3-[[(2,5-dimethyl-3-furanyl)-oxomethyl]amino]benzoic acid [no description available]	2.15	1	aromatic amide; furans
1-(4-ethoxyphenyl)-3-(6-quinoxalinyl)urea [no description available]	2.15	1	quinoxaline derivative
2-(dimethylsulfamoylamino)-9H-fluorene [no description available]	2.15	1	fluorenes
4-chloro-1-ethyl-3-nitro-2-quinolinone [no description available]	2.15	1	nitro compound; quinolines
4-chloro-3-nitro-1-(phenylmethyl)-2-quinolinone [no description available]	2.15	1	quinolines
2,5-dimethyl-1-(phenylmethyl)pyrrole-3,4-dicarboxaldehyde [no description available]	2.15	1	arenecarbaldehyde
2-(2-chloro-6-fluorophenyl)-1-(2,4-dihydroxyphenyl)ethanone [no description available]	2.15	1	stilbenoid
4-methyl-N-(3-nitrophenyl)-5-phenyl-3-thiophenecarboxamide [no description available]	2.15	1	aromatic amide
N-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-2,2,2-trichloroacetamide [no description available]	2.15	1	triazoles
N-(2-fluoro-5-methylphenyl)-3-phenylpropanamide [no description available]	2.15	1	anilide
N-[(4-fluorophenyl)methyl]-2-thiophen-2-ylacetamide [no description available]	2.15	1	organofluorine compound
4-tert-butyl-N-(1,4-dioxo-2,3-dihydrophthalazin-5-yl)benzamide [no description available]	2.15	1	phthalazines
N-[2-(2-methylpropyl)-1,3-dioxo-5-isoindolyl]-2-furancarboxamide [no description available]	2.15	1	phthalimides
6-(1,4,5,7-tetramethyl-6-pyrrolo[3,4-d]pyridazinyl)quinoline [no description available]	2.15	1	quinolines
2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone [no description available]	2.15	1	stilbenoid
5-(3-chloro-4-methylphenyl)-3-pyridin-4-yl-1,2,4-oxadiazole [no description available]	2.15	1	oxadiazole; ring assembly
5-(phenylmethyl)-3-(2-pyridinyl)-1,2,4-oxadiazole [no description available]	2.15	1	pyridines
2-methyl-5-(1-pyrrolidinyl)isoindole-1,3-dione [no description available]	2.15	1	phthalimides
(2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine) [no description available]	2.15	1	benzimidazoles
N-(4-bromo-2-fluorophenyl)-2-methyl-3-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
6,7,8,9-tetrahydro-5H-carbazole-3-carbohydrazide [no description available]	2.15	1	carbazoles
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide [no description available]	2.15	1	primary carboxamide; pyrazines; secondary carboxamide
N-(1,3-benzodioxol-5-yl)-5-methyl-2-furancarboxamide [no description available]	2.15	1	benzodioxoles
1-cyclohexyl-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea [no description available]	2.15	1	benzodioxine
8-[(2-methyl-5-nitro-1,2,4-triazol-3-yl)thio]quinoline [no description available]	2.15	1	aryl sulfide
1-[2-(2-chlorophenoxy)ethyl]benzimidazole [no description available]	2.15	1	benzimidazoles
4,5-dimethyl-2-[4-(3-nitrophenyl)-2-thiazolyl]-1H-pyrazol-3-one [no description available]	2.15	1	C-nitro compound
2-(4-fluoro-N-methylsulfonylanilino)-N-(3-methylphenyl)acetamide [no description available]	2.15	1	sulfonamide
1-(4-fluorophenyl)-2-(2-pyridinylthio)ethanone [no description available]	2.15	1	aromatic ketone
3-methyl-6-(1-pyrrolidinyl)-[1,2,4]triazolo[4,3-b]pyridazine [no description available]	2.15	1	triazolopyridazine
N-(3-acetylphenyl)-2-thiophen-2-ylacetamide [no description available]	2.15	1	aromatic ketone
oncrasin-1 oncrasin-1: an antineoplastic agent; structure in first source. oncrasin-1 : A member of the class of indoles that is 1H-indole substituted by 4-chlorobenzyl and formyl groups at positions 1 and 3, respectively. It is an anti-cancer agent that is active against lung cancer cells with K-Ras mutations.	2.15	1	arenecarbaldehyde; indoles; monochlorobenzenes	antineoplastic agent; apoptosis inducer
N-[2-(4-fluorophenyl)ethyl]-4-nitrobenzamide [no description available]	2.15	1	C-nitro compound
5-(1-methyl-2-benzimidazolyl)-2-thiophenecarboxaldehyde [no description available]	2.15	1	benzimidazoles
N-(4-anilinophenyl)-2-methylpropanamide [no description available]	2.15	1	anilide
N-(2-fluorophenyl)-3-phenylpropanamide [no description available]	2.15	1	anilide
1-[(Phenylthio)acetyl]piperidine [no description available]	2.15	1	N-acylpiperidine
N-(3-hydroxyphenyl)-5-methyl-3-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
3-(4-methoxyphenyl)-5-(4-methylphenyl)-1,2,4-oxadiazole [no description available]	2.15	1	oxadiazole; ring assembly
4-[(4-carboxy-2,6-dimethoxyphenoxy)methyl]-5-methyl-2-furancarboxylic acid [no description available]	2.15	1	trihydroxybenzoic acid
4-(4-morpholinylmethyl)-3-quinolinol [no description available]	2.15	1	quinolines
2-bromo-N-[3-(1-oxopropylamino)phenyl]benzamide [no description available]	2.15	1	benzamides
3-acetyl-2-methylbenzo[f]benzofuran-4,9-dione [no description available]	2.15	1	naphthofuran
5-(4-chlorophenyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide [no description available]	2.15	1	aromatic amide; heteroarene
1-azepanyl-[4-[(phenylthio)methyl]phenyl]methanone [no description available]	2.15	1	benzamides
1-(5-ethyl-2,4-dihydroxyphenyl)-2-(2-fluorophenoxy)ethanone [no description available]	2.15	1	aromatic ketone
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-nitrophenyl)acetamide [no description available]	2.15	1	acetamides
3,4,5-triethoxy-N-(1H-1,2,4-triazol-5-yl)benzamide [no description available]	2.15	1	benzamides
1-propylsulfonyl-4-(2-pyridinyl)piperazine [no description available]	2.15	1	piperazines; pyridines
2-(2-phenylethylthio)-3-pyridinecarboxylic acid [no description available]	2.15	1	aromatic carboxylic acid; pyridines
2-(2,3-dimethylphenoxy)-N-pyridin-4-ylacetamide [no description available]	2.15	1	aromatic ether
2-[[anilino(oxo)methyl]amino]-N-(phenylmethyl)benzamide [no description available]	2.15	1	benzamides
N-(5-acetyl-4-methyl-2-thiazolyl)-5-bromo-2-furancarboxamide [no description available]	2.15	1	thiazoles
1-cyclohexyl-3-(3-ethylphenyl)urea [no description available]	2.15	1	ureas
n-phenylpiracetam N-phenylpiracetam: structure given in first source	2.15	1
2-[(1-methyl-5-tetrazolyl)thio]-N-(2-phenylphenyl)acetamide [no description available]	2.15	1	biphenyls
N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-nitrobenzamide [no description available]	2.15	1	benzamides
4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-N-(2,6-dimethylphenyl)benzamide [no description available]	2.15	1	isoquinolines
5-(4-bromophenyl)-N-(2-methoxyphenyl)-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
3-[[(3,5-dichloro-4-ethoxyphenyl)-oxomethyl]amino]benzoic acid [no description available]	2.15	1	benzamides
1,4-bis(thiophen-2-ylsulfonyl)piperazine [no description available]	2.15	1	N-sulfonylpiperazine; thiophenes
2-bromo-N-[3-(1-oxobutylamino)phenyl]benzamide [no description available]	2.15	1	benzamides
1-(2-fluorophenyl)-4-[(6-nitro-1,3-benzodioxol-5-yl)methyl]piperazine [no description available]	2.15	1	piperazines
n-(1-benzyl-4-piperidinyl)-2,4-dichlorobenzamide N-(1-benzyl-4-piperidinyl)-2,4-dichlorobenzamide: inhibits the betaine-GABA transporter 1; structure in first source	2.15	1
2-[[2-(5-methyl-2-thiophenyl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone [no description available]	2.15	1	quinazolines
1-(2,1,3-benzothiadiazol-5-yl)-3-[4-(4-morpholinyl)phenyl]urea [no description available]	2.15	1	morpholines
ethyl 4-{N-[(4-chlorophenyl)sulfonyl]-N-methylglycyl}piperazine-1-carboxylate ethyl 4-{N-[(4-chlorophenyl)sulfonyl]-N-methylglycyl}piperazine-1-carboxylate : A sulfonamide in which the nitrogen carries methyl and 2-[4-(ethoxycarbonyl)piperazin-1-yl]-2-oxoethyl substituents and the sulfonyl a 4-chlorophenyl group.	2.15	1	carbamate ester; sulfonamide
LSM-4563 [no description available]	2.15	1	aromatic ketone
1-(4-chloro-3-methoxyphenyl)sulfonyl-4-phenylpiperazine [no description available]	2.15	1	piperazines
N-[4-[(3,4-dimethoxyphenyl)sulfamoyl]phenyl]acetamide [no description available]	2.15	1	sulfonamide
4-chloro-3-(1-piperidinylsulfonyl)-N-(2-thiazolyl)benzamide [no description available]	2.15	1	sulfonamide
1-(2,5-dimethoxyphenyl)sulfonyl-4-(phenylmethyl)piperazine [no description available]	2.15	1	sulfonamide
2-(4-methoxyphenyl)-N-[4-[(5-methyl-3-isoxazolyl)sulfamoyl]phenyl]acetamide [no description available]	2.15	1	sulfonamide
4-[4-(benzenesulfonyl)-1-piperazinyl]-2-methylquinoline [no description available]	2.15	1	piperazines; pyridines
1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone [no description available]	2.15	1	quinolines
N2-phenyl-6-[[(1-phenyl-5-tetrazolyl)thio]methyl]-1,3,5-triazine-2,4-diamine [no description available]	2.15	1	tetrazoles
2-[(4,6-dimethyl-2-pyrimidinyl)thio]-N-(4,5-diphenyl-2-oxazolyl)acetamide [no description available]	2.15	1	1,3-oxazoles
2-(4-bromophenyl)-1-[4-(2-pyridinyl)-1-piperazinyl]ethanone [no description available]	2.15	1	piperazines; pyridines
2-amino[1,3]thiazolo[4,5-d]pyrimidine-5,7-diol [no description available]	2.15	1	thiazolopyrimidine
3-[[(2-cyclohexyl-1,3-dioxo-5-isoindolyl)-oxomethyl]amino]benzoic acid [no description available]	2.15	1	aromatic amide
3-[[[3-(1-azepanylsulfonyl)-4-chlorophenyl]-oxomethyl]amino]benzoic acid [no description available]	2.15	1	benzamides
2-(4-bromophenyl)-N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)acetamide [no description available]	2.15	1	acetamides
5-(1,3-benzodioxol-5-ylsulfamoyl)-2-methoxybenzoic acid [no description available]	2.15	1	methoxybenzoic acid
N-cycloheptyl-1-(4-methylphenyl)sulfonyl-4-piperidinecarboxamide [no description available]	2.15	1	sulfonamide
3-(2-chlorophenyl)-5-methyl-N-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-4-isoxazolecarboxamide [no description available]	2.15	1	aromatic amide
N-[3-[[(4-nitrophenyl)-oxomethyl]amino]phenyl]-2-furancarboxamide [no description available]	2.15	1	benzamides
3-methyl-1,5-dithiophen-2-ylpentane-1,5-dione [no description available]	2.15	1	aromatic ketone
N-(2-methyl-1,3-benzothiazol-6-yl)-4-(4-morpholinylsulfonyl)benzamide [no description available]	2.15	1	sulfonamide
4-(dimethylsulfamoyl)-N-(4-thiophen-2-yl-2-thiazolyl)benzamide [no description available]	2.15	1	sulfonamide
3-chloro-N-[4-[(1-oxo-2-phenylethyl)amino]phenyl]benzamide [no description available]	2.15	1	benzamides
N-(3,4-dimethoxyphenyl)-4-[(4-phenyl-1-piperazinyl)methyl]benzamide [no description available]	2.15	1	benzamides
stk295900 [no description available]	2.15	1
1-(3-chlorophenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]piperazine [no description available]	2.15	1	piperazines
2-[4-[[4-(4-methoxyphenyl)-1-phthalazinyl]amino]phenyl]acetamide [no description available]	2.15	1	pyridazines; ring assembly
1-(2-fluorophenyl)-3-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]urea [no description available]	2.15	1	ureas
N-[5-[(4-methoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide [no description available]	2.15	1	methoxybenzenes
N-(1,3-benzodioxol-5-yl)-4-methyl-1-phthalazinamine [no description available]	2.15	1	phthalazines
N-[4-(4-morpholinyl)phenyl]carbamic acid butyl ester [no description available]	2.15	1	morpholines
4-(4-chlorophenoxy)-1-(4-morpholinyl)-1-butanone [no description available]	2.15	1	aromatic ether
4-(4-chlorophenoxy)-1-(1-piperidinyl)-1-butanone [no description available]	2.15	1	N-acylpiperidine
N-(3-phenylpropyl)methanesulfonamide [no description available]	2.15	1	benzenes
4-acetamido-N-(2-methoxyethyl)benzamide [no description available]	2.15	1	amidobenzoic acid
2-methyl-N-(2,3,4,5,6-pentafluorophenyl)-3-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
3,4-dihydro-2H-quinolin-1-yl-(4-propoxyphenyl)methanone [no description available]	2.15	1	quinolines
5-bromo-N-(2-phenylphenyl)-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
2-[2-(4-chlorophenoxy)ethylthio]pyrimidine [no description available]	2.15	1	aromatic ether
3-(3-bromoanilino)-1-(5-methyl-2-furanyl)-1-propanone [no description available]	2.15	1	aralkylamine
4-[2-(4-bromo-2-chlorophenoxy)-1-oxoethyl]-1-piperazinecarboxylic acid ethyl ester [no description available]	2.15	1	piperazinecarboxylic acid
2-[2-[[3-(1,3-benzoxazol-2-yl)anilino]-oxomethyl]phenyl]benzoic acid [no description available]	2.15	1	benzamides
1-[2-(2-chlorophenoxy)ethoxy]-2-methoxy-4-methylbenzene [no description available]	2.15	1	methoxybenzenes
N-[4-[(4-sulfamoylphenyl)sulfamoyl]phenyl]cyclopropanecarboxamide [no description available]	2.15	1	sulfonamide
4-[2-[2-(4-bromo-2-chlorophenoxy)ethoxy]ethyl]morpholine [no description available]	2.15	1	aromatic ether
N-[2-(2-phenylphenoxy)ethyl]-2-furancarboxamide [no description available]	2.15	1	biphenyls
5,6,7,8-tetrafluoro-2-(2,3,4,5,6-pentafluorophenyl)-4h-1-benzopyran-4-one 5,6,7,8-tetrafluoro-2-(2,3,4,5,6-pentafluorophenyl)-4H-1-benzopyran-4-one: structure in first source	2.15	1
2-[bis(5-methyl-2-furanyl)methyl]-6-nitrophenol [no description available]	2.15	1	nitrophenol
2-(4-nitrophenyl)-N-(2-oxolanylmethyl)-4-quinazolinamine [no description available]	2.15	1	quinazolines
2-(4-hydroxy-1,3-thiazol-2-yl)-1-phenylethan-1-one [no description available]	2.15	1	aromatic ketone
Methyl(2-furoylamino)acetic acid [no description available]	2.15	1	N-acyl-amino acid
5-nitro-8-(1-pyrrolidinyl)quinoline [no description available]	2.15	1	nitro compound; quinolines
2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide [no description available]	2.15	1	amino acid amide
2-[(4-methylphenyl)sulfonylamino]pentanoic acid [no description available]	2.15	1	sulfonamide
4,6-dimorpholino-n-(4-nitrophenyl)-1,3,5-triazin-2-amine 4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine: an mTOR activator; structure in first source	2.15	1
1-[(3-chlorophenyl)methyl]-N,N-diethyl-3-piperidinecarboxamide [no description available]	2.15	1	piperidines
1-(2,6-dimethyl-1-piperidinyl)-2-phenylethanone [no description available]	2.15	1	acetamides
2-amino-7-methyl-5-oxo-4-(2,3,4-trimethoxyphenyl)-4,6,7,8-tetrahydro-1-benzopyran-3-carbonitrile [no description available]	2.15	1	methoxybenzenes
3-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-1-phenylpyrrolidine-2,5-dione [no description available]	2.15	1	pyrrolidines
1-(4-bromophenyl)-3-(diethylamino)pyrrolidine-2,5-dione [no description available]	2.15	1	pyrrolidines
4-(5,6-diphenyl-1,2,4-triazin-3-yl)morpholine [no description available]	2.15	1	dialkylarylamine; tertiary amino compound
(3,5-Dimethyl-1-adamantyl)amine nitrate [no description available]	2.15	1	nitrates
1-(4-tert-butylphenoxy)-3-(1H-1,2,4-triazol-5-ylthio)-2-propanol [no description available]	2.15	1	alkylbenzene
N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-2-adamantanamine [no description available]	2.15	1	N-alkylpyrrolidine
4-phenyl-N-(pyridin-4-ylmethyl)-2-butanamine [no description available]	2.15	1	aralkylamine
N-(5-nitro-2-pyridinyl)cyclopropanecarboxamide [no description available]	2.15	1	aromatic amide
3-[(4-bromophenyl)methyl]-4-(4-methoxyanilino)-4-oxobutanoic acid [no description available]	2.15	1	anilide
3-ethyl-N-(2H-tetrazol-5-yl)-1-adamantanecarboxamide [no description available]	2.15	1	aromatic amide
N-(4-propan-2-ylphenyl)-3-bicyclo[2.2.1]heptanecarboxamide [no description available]	2.15	1	monoterpenoid
4-chloro-N-[2-(4-nitroanilino)ethyl]benzamide [no description available]	2.15	1	carbonyl compound; organohalogen compound
2-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-oxomethyl]-1-cyclohexanecarboxylic acid [no description available]	2.15	1	benzodioxine
2,4-dichloro-6-[1-(4-morpholinyl)-3-phenylprop-2-ynyl]phenol [no description available]	2.15	1	aromatic compound
2-[[1-(4-ethoxyphenyl)-2,5-dioxo-3-pyrrolidinyl]amino]acetonitrile [no description available]	2.15	1	pyrrolidines
1-ethoxy-3-(2-methoxy-4-prop-2-enylphenoxy)-2-propanol [no description available]	2.15	1	methoxybenzenes
6-amino-4-(3-chlorophenyl)-3-methyl-1-(phenylmethyl)-4H-pyrano[2,3-c]pyrazole-5-carbonitrile [no description available]	2.15	1	organochlorine compound; pyranopyrazole
1-(2-chlorophenoxy)-3-(2-methyl-1-benzimidazolyl)-2-propanol [no description available]	2.15	1	benzimidazoles
N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide [no description available]	2.15	1	hydroxyquinoline
N-(2-hydroxy-5-methylphenyl)-2-furancarboxamide [no description available]	2.15	1	aromatic amide; furans
4-amino-7,8,9,10-tetrahydro-6H-pyrimido[3,4]pyrrolo[3,5-a]azepine-11-carbonitrile [no description available]	2.15	1	organic heterobicyclic compound; organonitrogen heterocyclic compound
1-(3,5-dimethylphenyl)-3-(1H-1,2,4-triazol-5-ylthio)pyrrolidine-2,5-dione [no description available]	2.15	1	pyrrolidines
6-[(3,4-difluoroanilino)-oxomethyl]-1-cyclohex-3-enecarboxylic acid [no description available]	2.15	1	anilide
4-[(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)amino]-4-oxobutanoic acid [no description available]	2.15	1	organosulfur heterocyclic compound
[3-methyl-4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-thiophen-2-ylmethanone [no description available]	2.15	1	aromatic amide; thiophenes
[4-(2-methoxyphenyl)-1-piperazinyl]-[4-[(phenylthio)methyl]phenyl]methanone [no description available]	2.15	1	piperazines
N-(3,3,5-trimethylcyclohexyl)-1H-1,2,4-triazole-5-carboxamide [no description available]	2.15	1	aromatic amide; heteroarene
4-[2-nitro-5-[4-(phenylmethyl)sulfonyl-1-piperazinyl]phenyl]morpholine [no description available]	2.15	1	piperazines
5-(4-ethylsulfonyl-1-piperazinyl)-2-nitro-N-(3-pyridinylmethyl)aniline [no description available]	2.15	1	piperazines
2-[[5-[(1,3-benzothiazol-2-ylthio)methyl]-4-methyl-1,2,4-triazol-3-yl]thio]-N-[2-(4-morpholinyl)ethyl]acetamide [no description available]	2.15	1	benzothiazoles
N-ethyl-N-[2-[(5-nitro-8-quinolinyl)amino]ethyl]benzenesulfonamide [no description available]	2.15	1	nitro compound; quinolines
1-(4-methoxyphenyl)-N-(4-methyl-2-pyridinyl)-5-oxo-3-pyrrolidinecarboxamide [no description available]	2.15	1	pyrrolidines
3,4,5-trimethoxy-N-[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]benzamide [no description available]	2.15	1	benzamides
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene BRL-50481 : A C-nitro compound that is benzene substituted by N,N-dimethylaminosulfonyl, methyl and nitro groups at positions 1, 2 and 5, respectively. It is a phosphodiesterase inhibitor selective for the PDE7 subtype (Ki = 180 nM).	2.15	1	C-nitro compound; sulfonamide; toluenes	bone density conservation agent; EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor; geroprotector
6,3',4'-Trimethoxyflavanone [no description available]	2.15	1	ether; flavonoids
1-[4-(3-ethoxyphenoxy)butyl]imidazole [no description available]	2.15	1	aromatic ether
5-[[(1-cyclohexyl-5-tetrazolyl)thio]methyl]-3-phenyl-1,2,4-oxadiazole [no description available]	2.15	1	oxadiazole; ring assembly
2-[1-(3,4-dihydro-2H-quinolin-1-yl)-1-oxopropan-2-yl]isoindole-1,3-dione [no description available]	2.15	1	phthalimides
[4-(benzenesulfonyl)-1-piperazinyl]-(1-piperidinyl)methanone [no description available]	2.15	1	sulfonamide
3-(2,5-dioxo-1-pyrrolidinyl)-N-(2-methyl-1,3-dioxo-5-isoindolyl)benzamide [no description available]	2.15	1	amidobenzoic acid
6-[[[5-(ethylthio)-1,3,4-thiadiazol-2-yl]amino]-oxomethyl]-1-cyclohex-3-enecarboxylic acid [no description available]	2.15	1	aromatic amide
2,5-dimethoxy-n-(quinolin-3-yl)benzenesulfonamide 2,5-dimethoxy-N-(quinolin-3-yl)benzenesulfonamide: a tissue-nonspecific alkaline phosphatase inhibitor; structure in first source	2.15	1	quinolines
LSM-25805 [no description available]	2.15	1	isoindoles
4-ethoxy-N-(3-quinolinyl)benzenesulfonamide [no description available]	2.15	1	quinolines
3-chloro-N-[3-(1-imidazolyl)propyl]-6-nitro-1-benzothiophene-2-carboxamide [no description available]	2.15	1	1-benzothiophenes
nsc 727447 NSC 727447: structure in first source	2.15	1
2-methoxy-N-[(4-methylphenyl)methyl]-2-phenylacetamide [no description available]	2.15	1	acetamides
2-(4-chlorophenoxy)-N-(5-nitro-2-thiazolyl)acetamide [no description available]	2.15	1	C-nitro compound; thiazoles
7-(2-methoxyphenyl)-5-phenyl-1,7-dihydrotetrazolo[1,5-a]pyrimidine [no description available]	2.15	1	methoxybenzenes
N-[3-[2,5-dioxo-3-(phenylmethyl)-1-pyrrolidinyl]phenyl]acetamide [no description available]	2.15	1	pyrrolidines
3,4-dimethoxy-N-[3-(methylthio)phenyl]benzenesulfonamide [no description available]	2.15	1	sulfonamide
3-methyl-4-nitro-N-(1H-1,2,4-triazol-5-yl)benzamide [no description available]	2.15	1	C-nitro compound
2-[(4-chlorophenyl)methylthio]-N-(2-hydroxy-5-nitrophenyl)acetamide [no description available]	2.15	1	nitrophenol
2-(4-ethoxyphenyl)-N-[3-(1-imidazolyl)propyl]-4-quinolinecarboxamide [no description available]	2.15	1	quinolines
N-(4-bromophenyl)-5-methyl-4-nitro-1H-pyrazol-3-amine [no description available]	2.15	1	C-nitro compound
3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-2h-indol-2-one 3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-2H-indol-2-one: an estrogen receptor alpha inhibitor	2.15	1
d 609 [no description available]	2.03	1
N-[4-[(cyclohexylamino)-oxomethyl]phenyl]-3-pyridinecarboxamide [no description available]	2.15	1	aromatic amide
N,N,4-trimethyl-2-[[(5-methyl-2-furanyl)-oxomethyl]amino]-5-thiazolecarboxamide [no description available]	2.15	1	aromatic amide; thiazoles
ex 527 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.	2.15	1	carbazoles; monocarboxylic acid amide; organochlorine compound
3-[3-[(5-ethyl-[1,2,4]triazino[5,6-b]indol-3-yl)thio]propyl]-1H-benzimidazol-2-one [no description available]	2.15	1	indoles
4-methyl-2,7-diphenyl-8H-pyrido[2,3-d]pyrimidin-5-one [no description available]	2.15	1	phenylpyridine
3-methylharman [no description available]	2.15	1
1-methyl-beta-carboline-3-carboxylic acid 1-methyl-beta-carboline-3-carboxylic acid: metabolite from cows fed with corn silage; structure in first source	2.15	1
4-[2-[(6-chloro-4-quinazolinyl)amino]ethyl]phenol [no description available]	2.05	1	quinazolines
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.15	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
2-methyl-4(3h)-quinazolinone 2-methyl-4(3H)-quinazolinone: from Bacillus cereus; structure given in first source	2.15	1
n(4)-desoxychlordiazepoxide N(4)-desoxychlordiazepoxide: not phototoxic; structure given in first source	2.15	1
2-amino-3-hydroxyphenazine 2-amino-3-hydroxyphenazine: structure given in first source	2.15	1
2-styrylquinazolin-4(3h)-one 2-styrylquinazolin-4(3H)-one: structure given in first source	2.15	1
2-amino-5-iodo-6-phenyl-4-pyrimidinone [no description available]	2.15	1
quininib quininib: has antiangiogenic activity; structure in first source. quininib : A styrylquinoline that is trans-2-styrylquinoline in which the the phenyl group has been substituted at position 2 by a hydroxy group. It is an anti-angiogenic compound that exerts a dose-dependent antagonism of the cysteinyl leukotriene pathway, preferentially antagonising cysteinyl leukotriene receptor 1. The major species at pH 7.3	2.15	1	phenols; styrylquinoline	angiogenesis inhibitor
bropirimine [no description available]	2.15	1	pyrimidines
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-1H-quinazolin-4-one [no description available]	2.15	1	quinazolines
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-6-(methoxymethyl)-1H-pyrimidin-4-one [no description available]	2.15	1	quinazolines

Condition	Relationship Strength	Studies
Akinetic-Rigid Variant of Huntington Disease [description not available]	2.03	1
Huntington Disease A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)	2.03	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1
Infections, Pseudomonas [description not available]	2.1	1
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	2.1	1
Contact Dermatitis [description not available]	2.21	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.63	2
Itching [description not available]	2.21	1
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	2.21	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	2.21	1
Congenital Zika Syndrome [description not available]	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1

SMER 28

Description

Cross-References

Synonyms (63)

Roles (1)

Drug Classes (3)

Protein Targets (25)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (23)

Molecular Functions (12)

Ceullar Components (19)

Bioassays (63)

Research

Studies (20)

Market Indicators

Research Demand Index: 24.68

Study Types

SMER 28

Description

Cross-References

Synonyms (63)

Roles (1)

Drug Classes (3)

Protein Targets (25)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (23)

Molecular Functions (12)

Ceullar Components (19)

Bioassays (63)

Research

Studies (20)

Market Indicators

Research Demand Index: 24.68

Study Types

Related Drugs (553)

Related Conditions (15)